Drug intelligence / Profile preview

ENNO-0X

Development stage: Preclinical
Lead developer: Ennovate Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

ENNO-0X is an early-stage, preclinical bispecific antibody being developed by Ennovate Pharma, a joint venture co-founded by Enable Medicine and General Inception. The therapeutic candidate is designed to target the interleukin-1 receptor (IL1R) pathway through two internally coded components, EV01 and EV0X. By leveraging spatial biology and AI/ML-driven patient stratification, ENNO-0X is engineered to address the unmet needs of refractory and non-responder patients with autoimmune and inflammatory diseases who fail to respond to standard cytokine-based therapies. It is currently in the Hit stage of preclinical development.

Targets

EV01}

Beyond the preview

Go deeper on ENNO-0X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENNO-0X.

Explore the full profile